© 1993 by Oxford University Press
Journal of the National Cancer Institute, Vol. 85, No. 3, 200-206,
February 3, 1993
© 1993 Oxford University Press
Association of p53 Protein Expression With Tumor Cell Proliferation Rate and Clinical Outcome in Node-Negative Breast Cancer
Department of Pathology, University of Texas Health Science Center San Antonio
Department of Medicine/Oncology), University of Texas Health Science Center San Antonio
Department of Pathology, Baylor College of Medicine Houston, Tex.
W. L. McGuire is deceased
Correspondence to: D. Craig Allred, M.D., Department of Pathology, University of Texas Health Science Center, 7703 Floyd Curl Dr., San Antonio, TX 78284.
Background: The p53 (also known as TP53) tumor suppressor gene encodes for a nuclear phosphoprotein thought to regulate proliferation of normal cells. Most p53 mutations result in a nonfunctional protein that accumulates in tumor cell nuclei. These common mutations appear to be involved in the development and/or progression of several neoplastic diseases including human breast cancer. Purpose: Our purpose was to investigate the relationships between levels of mutant p53 protein expression, tumor cell proliferation rate, and clinical outcome in patients with node-negative breast cancer. Methods: Expression of mutant p53 protein was evaluated by frozen-section immunohistochemistry (IHC) and light microscopy in 700 breast cancers from axillary lymph node-negative patients with long-term follow-up (median, 54 months). The immunostaining signal was expressed as the sum of scores representing the proportion and staining intensity of negative and positive tumor cell nuclei (ranges, 0 and 2–8, respectively). Statistical comparisons were made between levels of p53 protein expression and disease-free survival, overall survival, and tumor proliferation rate expressed as the percentage of cells in the S phase (%S phase) as determined by flow cytometry. Results: Of the 700 tumors, 362 (52%) showed positive nuclear immunostaining (IHC score >0). Proliferation rates were significantly higher (P = .0001) in positive tumors (median %S phase, 7.1%) than in negative tumors (4.1%). In a univariate cutpoint analysis, negative tumors (n = 388) versus low-positive tumors (IHC score = 2–6; n = 263) versus high-positive tumors (IHC score >6; n = 99) showed progressively reduced disease-free survival (80% versus 72% versus 58% at 5 years, respectively; P
.05 for all pairwise comparisons). Analogous results for overall survival were 88% versus 84% versus 74%; only the result for negative versus high positive tumors was significant (P = .003). In a multivariate analysis, expression of p53 protein and high %S phase were independently associated with reduced disease-free survival (P = .008 and .01, respectively). Conclusions: Expression of mutant p53 protein was associated with high tumor proliferation rate, early disease recurrence, and early death in node-negative breast cancer. Despite the strong direct correlation between accumulation of p53 protein and tumor proliferation rate, both factors were independently associated with poor prognosis, suggesting that p53 may have other biological functions in addition to cell-cycle regulation. Implications: This test, when combined with other prognostic factors, may enhance our ability to identify node-negative breast cancer patients at high risk for early disease recurrence and/or death, for whom the use of adjuvant chemotherapy is unequivocally justified. [J Natl Cancer Inst 85:200–206, 1993]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. E. HERCEG, A. C. TSIATIS, J. L. HALPERN, G. E. HOLT, H. S. SCHWARTZ, V. L. KEEDY, and J. M.M. CATES Cyclooxygenase 2 Expression in Soft Tissue Leiomyosarcoma Anticancer Res, August 1, 2009; 29(8): 2913 - 2917. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Link, S. Balasubramaniam, A. Sharma, C. E.S. Comstock, S. Godoy-Tundidor, N. Powers, K. H. Cao, A. Haelens, F. Claessens, M. P. Revelo, et al. Targeting the BAF57 SWI/SNF Subunit in Prostate Cancer: A Novel Platform to Control Androgen Receptor Activity Cancer Res., June 15, 2008; 68(12): 4551 - 4558. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. C. Allred, Y. Wu, S. Mao, I. D. Nagtegaal, S. Lee, C. M. Perou, S. K. Mohsin, P. O'Connell, A. Tsimelzon, and D. Medina Ductal Carcinoma In situ and the Emergence of Diversity during Breast Cancer Evolution Clin. Cancer Res., January 15, 2008; 14(2): 370 - 378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-T. Liao, L.-B. Song, H.-Z. Zhang, X. Zhang, L. Zhang, W.-L. Liu, Y. Feng, B.-H. Guo, H.-Q. Mai, S.-M. Cao, et al. Centromere Protein H Is a Novel Prognostic Marker for Nasopharyngeal Carcinoma Progression and Overall Patient Survival Clin. Cancer Res., January 15, 2007; 13(2): 508 - 514. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V Malamou-Mitsi, H Gogas, U Dafni, A Bourli, T Fillipidis, M Sotiropoulou, D Vlachodimitropoulos, S Papadopoulos, O Tzaida, G Kafiri, et al. Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy Ann. Onc., October 1, 2006; 17(10): 1504 - 1511. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Allan, R. George, S. A. Vantyghem, M. W. Lee, N. C. Hodgson, C. J. Engel, R. L. Holliday, D. P. Girvan, L. A. Scott, C. O. Postenka, et al. Role of the Integrin-Binding Protein Osteopontin in Lymphatic Metastasis of Breast Cancer Am. J. Pathol., July 1, 2006; 169(1): 233 - 246. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. I. Pritchard, L. E. Shepherd, F. P. O'Malley, I. L. Andrulis, D. Tu, V. H. Bramwell, M. N. Levine, and the National Cancer Institute of Canada Clinical T HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy N. Engl. J. Med., May 18, 2006; 354(20): 2103 - 2111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.R. Darling, L. Jackson-Boeters, T.D. Daley, and E.P. Diamandis Human Kallikrein 6 Expression in Salivary Gland Tumors J. Histochem. Cytochem., March 1, 2006; 54(3): 337 - 342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Arpino, R. Laucirica, and R. M. Elledge Premalignant and In Situ Breast Disease: Biology and Clinical Implications Ann Intern Med, September 20, 2005; 143(6): 446 - 457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. C. Kaiser, M. Korner, A. Kappeler, and S. Aebi Retinoid receptors in ovarian cancer: expression and prognosis Ann. Onc., September 1, 2005; 16(9): 1477 - 1487. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Galanis, J. C. Buckner, M. J. Maurer, J. I. Kreisberg, K. Ballman, J. Boni, J. M. Peralba, R. B. Jenkins, S. R. Dakhil, R. F. Morton, et al. Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study J. Clin. Oncol., August 10, 2005; 23(23): 5294 - 5304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kawai, A. Ishii, K. Washiya, T. Konno, H. Kon, C. Yamaya, I. Ono, Y. Minamiya, and J. Ogawa Estrogen Receptor {alpha} and {beta} are Prognostic Factors in Non-Small Cell Lung Cancer Clin. Cancer Res., July 15, 2005; 11(14): 5084 - 5089. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M Ghosh, S. N Malik, R. G Bedolla, Y. Wang, M. Mikhailova, T. J Prihoda, D. A Troyer, and J. I Kreisberg Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation Endocr. Relat. Cancer, March 1, 2005; 12(1): 119 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Cappuzzo, E. Magrini, G. L. Ceresoli, S. Bartolini, E. Rossi, V. Ludovini, V. Gregorc, C. Ligorio, A. Cancellieri, S. Damiani, et al. Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung Cancer J Natl Cancer Inst, August 4, 2004; 96(15): 1133 - 1141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. I. Kreisberg, S. N. Malik, T. J. Prihoda, R. G. Bedolla, D. A. Troyer, S. Kreisberg, and P. M. Ghosh Phosphorylation of Akt (Ser473) is an Excellent Predictor of Poor Clinical Outcome in Prostate Cancer Cancer Res., August 1, 2004; 64(15): 5232 - 5236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. F. Faneyte, J. L. Peterse, H. van Tinteren, C. Pronk, E. G. E. de Vries, S. Rodenhuis, and M. J. van de Vijver Predicting Early Failure after Adjuvant Chemotherapy in High-Risk Breast Cancer Patients with Extensive Lymph Node Involvement Clin. Cancer Res., July 1, 2004; 10(13): 4457 - 4463. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Green, K. V. Desai, Yumei Ye, C. Kavanaugh, A. Calvo, and J.-I. Huh Application of Gene Expression Profiling for Validating Models of Human Breast Cancer Toxicol Pathol, January 1, 2004; 32(1_suppl): 84 - 89. [Abstract] [PDF]
|
|
|
|
|
|
J. Sun, J. Ohkanda, D. Coppola, H. Yin, M. Kothare, B. Busciglio, A. D. Hamilton, and S. M. Sebti Geranylgeranyltransferase I Inhibitor GGTI-2154 Induces Breast Carcinoma Apoptosis and Tumor Regression in H-Ras Transgenic Mice Cancer Res., December 15, 2003; 63(24): 8922 - 8929. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H P Kourea, A K Koutras, C D Scopa, M N Marangos, E Tzoracoeleftherakis, D Koukouras, and H P Kalofonos Expression of the cell cycle regulatory proteins p34cdc2, p21waf1, and p53 in node negative invasive ductal breast carcinoma Mol. Pathol., December 1, 2003; 56(6): 328 - 335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Liao and M.-C. Hung Regulation of the Activity of p38 Mitogen-Activated Protein Kinase by Akt in Cancer and Adenoviral Protein E1A-Mediated Sensitization to Apoptosis Mol. Cell. Biol., October 1, 2003; 23(19): 6836 - 6848. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Bazan, M. Migliavacca, I. Zanna, C. Tubiolo, N. Grassi, M. A. Latteri, M. La Farina, I. Albanese, G. Dardanoni, S. Salerno, et al. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype Ann. Onc., September 1, 2002; 13(9): 1438 - 1446. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Burke, S. J. DeNardo, L. A. Miers, K. R. Lamborn, S. Matzku, and G. L. DeNardo Cilengitide Targeting of {alpha}v{beta}3 Integrin Receptor Synergizes with Radioimmunotherapy to Increase Efficacy and Apoptosis in Breast Cancer Xenografts Cancer Res., August 1, 2002; 62(15): 4263 - 4272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Van Poznak, L. Tan, K. S. Panageas, C. D. Arroyo, C. Hudis, L. Norton, and A. D. Seidman Assessment of Molecular Markers of Clinical Sensitivity to Single-Agent Taxane Therapy for Metastatic Breast Cancer J. Clin. Oncol., May 1, 2002; 20(9): 2319 - 2326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. N. Malik, M. Brattain, P. M. Ghosh, D. A. Troyer, T. Prihoda, R. Bedolla, and J. I. Kreisberg Immunohistochemical Demonstration of Phospho-Akt in High Gleason Grade Prostate Cancer Clin. Cancer Res., April 1, 2002; 8(4): 1168 - 1171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Schnitt Traditional and Newer Pathologic Factors J Natl Cancer Inst Monographs, December 1, 2001; 2001(30): 22 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Bast Jr, P. Ravdin, D. F. Hayes, S. Bates, H. Fritsche Jr, J. M. Jessup, N. Kemeny, G. Y. Locker, R. G. Mennel, and M. R. Somerfield 2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology J. Clin. Oncol., March 15, 2001; 19(6): 1865 - 1878. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Loprinzi and S. D. Thome Understanding the Utility of Adjuvant Systemic Therapy for Primary Breast Cancer J. Clin. Oncol., February 15, 2001; 19(4): 972 - 979. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Pich, E. Margaria, and L. Chiusa Oncogenes and Male Breast Carcinoma: c-erbB-2 and p53 Coexpression Predicts a Poor Survival J. Clin. Oncol., August 16, 2000; 18(16): 2948 - 2956. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Fabian, B. F. Kimler, C. M. Zalles, J. R. Klemp, S. Kamel, S. Zeiger, and M. S. Mayo Short-Term Breast Cancer Prediction by Random Periareolar Fine-Needle Aspiration Cytology and the Gail Risk Model J Natl Cancer Inst, August 2, 2000; 92(15): 1217 - 1227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. E. Fernando, X. Wu, and L. S. Perera p53 Overexpression and Steroid Hormone Receptor Status in Endometrial Carcinoma International Journal of Surgical Pathology, July 1, 2000; 8(3): 213 - 222. [Abstract] [PDF]
|
|
|
|
|
|
R. C. Zellars, S. G. Hilsenbeck, G. M. Clark, D. C. Allred, T. S. Herman, G. C. Chamness, and R. M. Elledge Prognostic Value of p53 for Local Failure in Mastectomy-Treated Breast Cancer Patients J. Clin. Oncol., May 9, 2000; 18(9): 1906 - 1913. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Linderholm, K. Grankvist, N. Wilking, M. Johansson, B. Tavelin, and R. Henriksson Correlation of Vascular Endothelial Growth Factor Content With Recurrences, Survival, and First Relapse Site in Primary Node-Positive Breast Carcinoma After Adjuvant Treatment J. Clin. Oncol., April 7, 2000; 18(7): 1423 - 1431. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. Diab, R. M. Elledge, and G. M. Clark Tumor Characteristics and Clinical Outcome of Elderly Women With Breast Cancer J Natl Cancer Inst, April 5, 2000; 92(7): 550 - 556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Nemunaitis, S. G. Swisher, T. Timmons, D. Connors, M. Mack, L. Doerksen, D. Weill, J. Wait, D. D. Lawrence, B. L. Kemp, et al. Adenovirus-Mediated p53 Gene Transfer in Sequence With Cisplatin to Tumors of Patients With Non-Small-Cell Lung Cancer J. Clin. Oncol., February 1, 2000; 18(3): 609 - 609. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Gobbi, W. D. Dupont, J. F. Simpson, W.D. Plummer Jr., P. A. Schuyler, S. J. Olson, C. L. Arteaga, and D. L. Page Transforming Growth Factor-{beta} and Breast Cancer Risk in Women With Mammary Epithelial Hyperplasia J Natl Cancer Inst, December 15, 1999; 91(24): 2096 - 2101. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Crosier, D. Scott, R. G. Wilson, C. D. M. Griffiths, F. E. B. May, and B. R. Westley Differences in Ki67 and c-erbB2 Expression between Screen-detected and True Interval Breast Cancers Clin. Cancer Res., October 1, 1999; 5(10): 2682 - 2688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Spurdle, G. S. Dite, X. Chen, C. J. Mayne, M. C. Southey, L. E. Batten, H. Chy, L. Trute, M. R. E. McCredie, G. G. Giles, et al. Androgen Receptor Exon 1 CAG Repeat Length and Breast Cancer in Women Before Age Forty Years J Natl Cancer Inst, June 2, 1999; 91(11): 961 - 966. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Harvey, G. M. Clark, C. K. Osborne, and D. C. Allred Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer J. Clin. Oncol., May 1, 1999; 17(5): 1474 - 1474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Armes, L. Trute, D. White, M. C. Southey, F. Hammet, A. Tesoriero, A.-M. Hutchins, G. S. Dite, M. R. E. McCredie, G. G. Giles, et al. Distinct Molecular Pathogeneses of Early-Onset Breast Cancers in BRCA1 and BRCA2 Mutation Carriers: A Population-based Study Cancer Res., April 1, 1999; 59(8): 2011 - 2017. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-l. Huang, N. Kohno, E. Ogawa, M. Adachi, T. Taki, and M. Miyake Correlation of Reduction in MRP-1/CD9 and KAI1/CD82 Expression with Recurrences in Breast Cancer Patients Am. J. Pathol., September 1, 1998; 153(3): 973 - 983. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. S. Bharaj, K. Angelopoulou, and E. P. Diamandis Rapid sequencing of the p53 gene with a new automated DNA sequencer Clin. Chem., July 1, 1998; 44(7): 1397 - 1403. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Williams, T. Norberg, A. Ahmadian, F. Ponten, J. Bergh, M. Inganas, J. Lundeberg, and M. Uhlen Assessment of sequence-based p53 gene analysis in human breast cancer: messenger RNA in comparison with genomic DNA targets Clin. Chem., March 1, 1998; 44(3): 455 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Freeman, J. T. Colston, M. Zabalgoitia, and B. Chandrasekar Contractile depression and expression of proinflammatory cytokines and iNOS in viral myocarditis Am J Physiol Heart Circ Physiol, January 1, 1998; 274(1): H249 - H258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Robbins p53 and Breast Cancer International Journal of Surgical Pathology, October 1, 1996; 4(2): 93 - 110. [Abstract] [PDF]
|
|
|
|
|
|
H. B. Muss, A. D. Thor, D. A. Berry, T. Kute, E. T. Liu, F. Koerner, C. T. Cirrincione, D. R. Budman, W. C. Wood, M. Barcos, et al. c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer N. Engl. J. Med., May 5, 1994; 330(18): 1260 - 1266. [Abstract] [Full Text]
|
|
|
|
|
|
C. C. Harris and M. Hollstein Clinical Implications of the p53 Tumor-Suppressor Gene N. Engl. J. Med., October 28, 1993; 329(18): 1318 - 1327. [Full Text]
|
|